首页> 外文OA文献 >Outcomes of High-Risk Prostate Cancer Patients at Hakodate Goryoukaku Hospital
【2h】

Outcomes of High-Risk Prostate Cancer Patients at Hakodate Goryoukaku Hospital

机译:函馆高邮阁医院高危前列腺癌患者的治疗效果

摘要

We assessed the outcomes of high-risk prostate cancer patients who received radical prostatectomy (RP), external beamradiation therapy (EBRT) or androgen deprivation therapy (ADT). Two hundred nineteen patients who were diagnosed with pathologically confirmed high-risk prostate cancer as defined by D’Amico between 2005 and 2011 were included in this study. Of them, 74 patients underwent RP. The 5-year cancer-specific survival (5yCSS) and 5-year PSA recurrence-free survival (5yPRFS) rates were 100 and 67.2%, respectively. A positive surgical margin and Gleason score≧8 were risk factors for PSA recurrence. The 5yPRFSs were 100, 74.4% and ‘unmeasurable’ for patients with 0, 1 and 2 risk factors, respectively. Ninety patients underwent EBRT. The 5yCSS and 5yPRFS rates were 95.2 and 74.2%, respectively. Fifty-five patients underwent ADT alone. Their 5yCSS and 5yPRFS rates were 93. 3 and 64. 3%, respectively. There was no significant difference in 5yCSS and 5yPRFS rates among the treatment groups. These results show that RP can be a treatment option for high-risk prostate cancer patients.
机译:我们评估了接受前列腺癌根治术(RP),外部束放射疗法(EBRT)或雄激素剥夺疗法(ADT)的高危前列腺癌患者的预后。这项研究包括了2005年至2011年间D'Amico定义的经病理证实为高危前列腺癌的119名患者。其中74例接受了RP。 5年癌症特异性生存率(5yCSS)和5年PSA无复发生存率(5yPRFS)分别为100%和67.2%。手术切缘阳性和格里森评分≥8是PSA复发的危险因素。对于具有0、1、2危险因素的患者,5yPRFS分别为100%,74.4%和“不可测量”。 90名患者接受了EBRT。 5yCSS和5yPRFS的比率分别为95.2%和74.2%。 55名患者仅接受ADT治疗。他们的5yCSS和5yPRFS比率分别为93. 3和64. 3%。治疗组之间的5yCSS和5yPRFS率无显着差异。这些结果表明,RP可以作为高危前列腺癌患者的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号